Utvalda Publikationer

EAK Fletcher, W van Maren, R Cordfunke, J Dinkelaar, JDC Codee, G van der Marel, CJM Melief, F Ossendorp, JW Drijfhout, SM Mangsbo. Formation of immune-complexes with a tetanus-derived B cell epitope boosts human T cell responses to covalently-linked peptides in an ex-vivo blood loop system. In press Journal of Immunology 2018

Mangsbo SM, Fletcher EAK, van Maren WWC, Redeker A, Cordfunke RA, Dillmann I, Dinkelaar J, Ouchaou K, Codee JDC, van der Marel GA, Hoogerhout P, Melief CJM, Ossendorp F, Drijfhout JW. Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses. Mol Immunol. 2018 Jan;93:115-124

Fletcher EAK, Eltahir M, Lindqvist F, Rieth J, Törnqvist G, Leja-Jarblad J, Mangsbo SM. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics. Int Immunopharmacol. 2018 Jan;54:1-11.

van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SM. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. Eur J Immunol. 2017 Feb;47(2):385-393.

van Hooren L, Georganaki M, Huang H, Mangsbo SM, Dimberg A. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. Oncotarget. 2016 Jul 1;7(31):50277-50289. doi: 10.18632/oncotarget.10364.

Mangsbo SM, Broos S, Fletcher E, Veitonmaki N, Furebring C, Dahlen E, Norlen P, Lindstedt M, Totterman TH, Ellmark P. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity. Clin Cancer Res. 2015 Mar 1;21(5):1115-26.

Liljenfeldt L, Yu D, Chen L, Essand M, Mangsbo SM. A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells. J Immunother. 2014 Apr;37(3):155-62.

Sandin L, Eriksson F, Ellmark P, Loskog A, Tötterman TH, Mangsbo SM. Local CTLA-4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology 2014 Jan 1;3(1):e27614.

van Montfoort N, Mangsbo SM, Camps MGM, van Maren WWC, Verhaart IEC, Waisman A, Drijfhout JW, Melief CJM, Verbeek JS, Ossendorp F. Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo. Eur J Immunol. 2012 Mar;42(3):598-606     contributed equally as first authors

Mangsbo SM, Sandin L, Anger K, Korman A, Loskog A, Tötterman TH. Enhanced tumor eradication by combining CTLA4 or PD1 blockade with CpG therapy. J Immunother. 2010 Apr;33 (3):225‐35.

Senast uppdaterad: 2022-01-12